RLYB vs. JAGX, HOOK, TPST, ASMB, SCYX, VTVT, MRNS, IFRX, SLS, and AFMD
Should you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include Jaguar Health (JAGX), Hookipa Pharma (HOOK), Tempest Therapeutics (TPST), Assembly Biosciences (ASMB), SCYNEXIS (SCYX), vTv Therapeutics (VTVT), Marinus Pharmaceuticals (MRNS), InflaRx (IFRX), SELLAS Life Sciences Group (SLS), and Affimed (AFMD). These companies are all part of the "pharmaceutical preparations" industry.
Rallybio (NASDAQ:RLYB) and Jaguar Health (NASDAQ:JAGX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation, analyst recommendations and community ranking.
Rallybio presently has a consensus price target of $12.20, suggesting a potential upside of 555.91%. Given Rallybio's higher possible upside, analysts clearly believe Rallybio is more favorable than Jaguar Health.
Jaguar Health has higher revenue and earnings than Rallybio.
Rallybio has a beta of -1.63, indicating that its stock price is 263% less volatile than the S&P 500. Comparatively, Jaguar Health has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.
In the previous week, Rallybio had 3 more articles in the media than Jaguar Health. MarketBeat recorded 14 mentions for Rallybio and 11 mentions for Jaguar Health. Rallybio's average media sentiment score of 0.51 beat Jaguar Health's score of 0.24 indicating that Rallybio is being referred to more favorably in the media.
90.3% of Rallybio shares are held by institutional investors. Comparatively, 12.0% of Jaguar Health shares are held by institutional investors. 7.4% of Rallybio shares are held by insiders. Comparatively, 0.0% of Jaguar Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Jaguar Health received 1802 more outperform votes than Rallybio when rated by MarketBeat users. Likewise, 89.08% of users gave Jaguar Health an outperform vote while only 73.33% of users gave Rallybio an outperform vote.
Rallybio has a net margin of 0.00% compared to Jaguar Health's net margin of -423.11%. Rallybio's return on equity of -66.59% beat Jaguar Health's return on equity.
Summary
Rallybio beats Jaguar Health on 9 of the 14 factors compared between the two stocks.
Get Rallybio News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rallybio Competitors List
Related Companies and Tools
